Skip to main content
. Author manuscript; available in PMC: 2010 Mar 1.
Published in final edited form as: J Allergy Clin Immunol. 2009 Mar;123(3):612–618. doi: 10.1016/j.jaci.2008.12.006

FIG 5.

FIG 5

Role of β-glucan structures in HDM-induced CCL20 production. A, CCL20 secretion from 16HBE14o-cells treated with HDM, zymosan (Zym), laminarin (Lam), curdlan (Curd), and a combination of these β-glucans. *P < .001 vs control and ††P < .001 vs HDM. B, Dose-dependent inhibition of HDM-induced CCL20 secretion by laminarin. *P < .001 vs control and ††P < .001 vs HDM. C, Decreased CCL20 production by 16HBE14o- cells exposed to HDM pretreated with a β-glucanase. **P < .001 vs control, †P < .001 vs HDM, and §P < .01 vs maleic acid plus HDM. D, CCL20 secretion from HDM-exposed 16HBE14o- cells pretreated with the Syk inhibitor piceatannol (4 μmol/L final concentration). †P < .001 vs HDM. ctrl, Control.